Genmab — August 2012
-
excellent progress in partner progressions with dara
-
forventer inden udgangen af året
-
det marked som Dara sigter mod
-
Så er der Arzerra ( som er blevet 3.hjul!) insane
-
vil stige fra 3,9 i år til 9 i 2020
-
Multiple Myloema
-
Nu også i Argentina
-
24 lande
-
Nu er den slide jeg lagde i debatten
-
Steady stream of data
-
fra både dem selv/gsk og partnerstudie
-
response rates fra 82-100%
-
fra både kendte og ukendte kombinationsstudier
-
2013 først phase III
-
substantial increase i arzerra sales
-
Readout! i 2013
-
expected
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind